SA News • Tue, Nov. 11
Be smarter and faster with PRO Alerts on TKPYY
From other sites
at Zacks.com (Nov 11, 2014)
at Zacks.com (Nov 6, 2014)
at Zacks.com (Oct 31, 2014)
at CNBC.com (Apr 9, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Apr 8, 2014)
There are no Focus articles on TKPYY.
Tue, Nov. 11, 11:22 AM
- Takeda Pharmaceuticals (OTCPK:TKPHF) (OTCPK:TKPYY) and GE Healthcare form a partnership focused on hepatic fibrosis research and development. Under the terms of the alliance agreement, GE will provide diagnostic imaging technology to Takeda for use in generating a liver stiffness map that the latter is developing as part of its research. The objective is to leverage the strengths of the two companies to develop new therapeutics and diagnostic technologies for liver diseases.
- One goal is to develop a way to measure the relative stiffness of liver tissue without having to perform a biopsy. MR elastography, for example, has the potential to be a reliable non-invasive way to do this.
Tue, Oct. 28, 8:26 AM
- U.S. District Judge Rebecca Doherty agreed withe jury that Takeda (OTCPK:TKPHF) (OTCPK:TKPYY) and Eli Lilly (NYSE:LLY) hid the cancer risks of its diabetes drug Actos (pioglitazone), but cut the punitive damages award from $9B to $36.8M, the maximum a jury could award under current U.S. law. The judge denied the firms' request for a new trial.
- Takeda faces more than 8,000 lawsuits in the U.S. accusing it of mishandling Actos.
Wed, Oct. 22, 11:31 AM
- The European Commission approves privately-held Switzerland-based Ferring Pharmaceuticals' Cortiment (budesonide) for the induction of remission in patients with active mild-to-moderate ulcerative colitis. Budesonide is a locally acting glucocorticosteroid.
- Ferring licensed Cortiment from Cosmo Pharmaceuticals SpA for the EU, Asia (ex-Japan), Australia, Canada, Latin America and Africa. The product is sold under the brand name Uceris in the U.S. by Salix Pharmaceuticals (SLXP -0.2%).
- UC-related tickers: (NASDAQ:VBLX) (RCPT)(OTCPK:TKPHF)(OTCPK:TKPYY +0.2%)(ATHX +2.3%)(SHPG +1.3%)(PFE +0.7%)(ABT -0.4%)(ABBV +1.2%)(CNDO +1.1%)(JNJ +1%)(SGYP -3.2%)
Tue, Oct. 21, 10:52 AM
- The FDA accepts Eli Lilly's NDA for empagliflozin plus immediate-release metformin hydrochloride for the treatment of adults with type 2 diabetes (T2D). The product is part of the Lilly/Boehringer Ingelheim Diabetes alliance portfolio.
- Empagliflozin is a sodium glucose co-transporter-2 inhibitor which removes excess glucose through the urine by blocking glucose reabsorption in the kidney. Metformin decreases the production of glucose in the liver and its absorption in the intestine and improves the body's ability to utilize glucose.
- The FDA approved Jardiance (empagliflozin) as an adjunct to diet and exercise to improve glycemic control in adults with T2D in August 2014. Metformin has been in clinical use for many years.
- Diabetes-related tickers: (JNJ +0.4%)(OTCQB:ISLT)(OTCQB:BTHE +20%)(VTAE +2.5%)(NVO +0.5%)(MRK +0.9%)(NASDAQ:VKTX)(HPTX +0.4%)(ABT +1.2%)(OTCPK:TKPHF)(OTCPK:TKPYY -0.5%)(MDT +1.7%)(SNY -0.2%)(OTCQB:SNYNF -0.5%)(MNKD +2.4%)(ALR +1.4%)(TNDM +3%)
Wed, Oct. 15, 10:33 AM
- Orexigen Therapeutics (OREX +6.4%) earns a $70M milestone payment from Takeda Pharmaceuticals (OTCPK:TKPHF -0.8%)(OTCPK:TKPYY -0.7%) triggered by the shipment of Contrave (naltrexone HCI and bupropion HCI extended release) to pharmacy wholesalers in preparation for commercial launch. It earned a $30M milestone triggered by FDA approval on October 7.
- Orexigen expects to end 2014 with ~$190M in quick assets.
Thu, Oct. 9, 1:29 PM
- The FDA approves Takeda Pharmaceutical Compnay's (OTCPK:TKPHF)(OTCPK:TKPYY -1.2%) Velcade (bortezomib) injection for treatment-naive patients with mantle cell lymphoma (MCL). Velcade is the first treatment approved in the U.S. for this indication.
- The product was previously approved for the treatment of multiple myeloma and relapsed mantle cell lymphoma.
- Velcade is co-developed by Milliennium/Takeda and Janssen Pharmaceutical Cos. Millennium is responsible for its commercialization in the U.S. and Janssen ex-U.S.
Tue, Oct. 7, 9:54 AM
- Menlo Park, CA-based Virobay (VBAY) is set for its IPO of 3.8M shares at $12 - 14.
- The clinical stage biopharmaceutical firm develops drugs based on its cysteine cathepsin platform. Cysteine cathepsins are important enzymes in the biology of many diseases. The company believes that inhibiting these enzymes produces safer, more effective therapies. It currently focuses its efforts on inhibitors of cathepsins S and B.
- Its lead product candidates are cathepsin S inhibitors: VBY-036 for neuropathic pain and Crohn's disease and VBY-891 for psoriasis. Phase 2 development for all three indications should commence in 1H 2015 which means that meaningful product revenues are far in the distance.
- In 2013, the company generated $9.9M in collaboration revenue. Its operating loss was ($2.3M). In 1H 2015, collaboration revenue dropped to $1.1M and the loss from operations increased to ($3.6M).
- Crohn's disease-related tickers: (ABBV -1.6%)(MRK -1.2%)(RDHL +0.4%)(VBLX)(OTCPK:TKPHF)(OTCPK:TKPYY)(CNDO +1.1%)(OTCQB:SNGX)(PSTI +2.3%)
- Neuropathic pain-related tickers: (DARA -4.4%)(AVNR -3.4%)(ZLCS +0.9%)(IPCI -2%)(BLRX -1.9%)(MNOV +0.6%)(PFE -0.3%)(OTCPK:NGSX)
- Psoriasis-related tickers: (DERM -0.5%)(NVS -2.5%)(CELG -1.4%)(LLY -1.3%)(CANF -2.3%)(IDRA -1.4%)(JNJ -0.8%)(XNPT +0.5%)(HSP -0.2%)
Fri, Oct. 3, 4:34 AM
- From the press release: "Takeda (OTCPK:TKPHF, OTCPK:TKPYY) has previously openly addressed through announcements and press conferences that, regarding the CASE-J study, an investigator-initiated sponsored research (IISR) related to the Takeda's hypertension medicine Blopress (candesartan cilexetil), certain inappropriate promotional activities utilizing the results of this research were found to have occurred." See the PR for its plans for preventing further inappropriate promotion.
- "For related directors, depending on their individual scope of responsibility, a reduction of monthly remuneration within the range of 5% to 20% will be imposed for three months."
Thu, Jun. 19, 9:16 AM
- Citing a failure to demonstrate a statistically significant improvement in overall survival (OS), Takeda Pharmaceutical Company Ltd (TKPYY) terminates its orteronel development program for prostate cancer. The firm's decision is not unexpected considering its disclosure in 2013 that an interim analysis of the results of the Phase 3 ELM-PC5 clinical trial showed that orteronel would be unlikely to meet its primary endpoint of OS compared to placebo.
Fri, May. 23, 2:39 PM
- Takeda Pharmaceuticals (TKPHF, TKPYY) yesterday was found not liable for the bladder cancer of two women who used its Actos diabetes medication, as a Nevada jury agreed with the company that the drug did not cause the women’s disease.
- A jury last month ordered Takeda and partner Eli Lilly (LLY) to pay more than $9B in damages to a plaintiff - Takeda is appealing the verdict - but the company has won the other five cases that have gone to trial over Actos' alleged link to bladder cancer.
- Takeda still faces claims by more than 7,000 plaintiffs.
Tue, Apr. 8, 3:07 AM
- A jury has ordered Japan's Takeda (TKPYY) to pay $6B and Eli Lilly (LLY) $3B in punitive damages over allegations that they hid the cancer risks associated with the diabetes therapy Actos.
- However, Eli Lilly could be off the hook, as Takeda agreed to indemnify Lilly for any legal liability connected to Actos.
- In addition, the award is likely to be cut on appeal, as the Supreme Court has set limits on punitive verdicts.
- In two previous cases, judges quashed multi-million dollar awards against Actos.
- Notwithstanding, Takeda's shares slumped 5.2% in Tokyo.
Tue, Feb. 4, 8:28 AM
- Ten major pharmaceuticals companies are getting together with the National Institutes of Health and other organizations in a five-year partnership that will look to understand the science behind Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus.
- In an unusual move, the normally secretive participants will share scientists, tissue, blood samples and data, with the aim being to identify targets for new drugs.
- The firms involved include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Takeda (TKPHF) and Sanofi (SNY).
- Those that haven't joined include Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
Dec. 27, 2013, 7:51 AM
- "The company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam do not outweigh the potential risks,” Takeda (TKPHF) says, ending development of its late-stage GPR40 agonist TAK-875.
- The drug was tied to liver damage.
- The company had hoped the treatment would help offset revenue lost to generic Actos, the diabetes drug which at one time accounted for more than a quarter of Takeda's top-line.
- Shares fell 5%+ in Tokyo on the news.
Dec. 1, 2013, 2:50 AM
- Japan's Takeda Pharmaceutical (TKPHF) has named 20-year GlaxoSmithKline veteran Christophe Weber as the candidate to become its next CEO.
- Assuming Takeda's shareholders approve the appointment of Weber, the French national is set to become the company's first non-Japanese leader in its 232-year history.
- Weber, who is the president of GSK's vaccines division in Belgium, will become Takeda's COO by April, its president in June, and its CEO in 2015. (PR)
Jun. 10, 2013, 7:37 AMVia the European Decentralized Procedure (Netherlands is the Reference Member State), Apricus (APRI) gets its ED treatment Vitaros approved. The company believes it will "capture a significant share of the ~$1B PDE-5 inhibitor market." APRI says it will work with partners Sandoz, Takeda (TKPHF.PK), and Bracco to obtain national phase approvals. Shares +9.38% premarket. (PR) | Comment!
Mar. 19, 2013, 8:18 AMNPS Pharmaceuticals (NPSP) has bought back the none-North American rights to two drugs from Takeda for $50M in shares and possible milestone payments, giving NPS with full global rights to the treatments. The drugs are Revestive (Gattex in the U.S.), a medicine for short bowel syndrome, and Preotact, a thyroid hormone replacement therapy. (PR) | Comment!
There are no StockTalks on this stock yet.
TKPYY vs. ETF Alternatives
Other News & PR